

## **Gastrointestinal Cancers Symposium Disclosure**

In compliance with the ASCO Conflict of Interest Policy and the Accreditation Council for Continuing Medical Education (ACCME) Standard for Commercial Support, abstract authors and discussants who participate in any ASCO- or co-sponsored meeting must disclose financial interests and other relationships with entities that have an investment, licensing, or other commercial interest in the subject matter under consideration in their abstract or presentation. Author and faculty disclosures may be published in ASCO publications where appropriate.

Authors and faculty will be asked to disclose financial interests and other relationships in the following categories:

### **Items Requiring Disclosure**

#### **A. Employment or Leadership Position**

Any full- or part-time employment or service as an officer or board member for an entity having an investment, licensing, or other commercial interest in the subject matter under consideration must be disclosed.

#### **B. Advisory Role**

Consultant or advisory arrangements with an entity having an investment, licensing, or other commercial interest in the subject matter under consideration must be disclosed if consultation was performed or payments made for such consultation within 2 years of the activity or subject matter in question.

#### **C. Stock Ownership**

Any ownership interest (except when invested in a diversified fund not controlled by the covered individual) in a start-up company, the stock of which is not publicly traded, or in any publicly traded company must be disclosed if the company is an entity having an investment, licensing, or other commercial interest in the subject matter under consideration.

#### **D. Honoraria**

Honoraria are reasonable payments for specific speeches, seminar presentations, or appearances. Disclosure of honoraria is required when paid directly to the covered individual by an entity having an investment, licensing, or other commercial interest in the subject matter under consideration and when provided within 2 years of the activity or subject matter in question.

#### **E. Research Funding**

All payments associated with the conduct of the clinical research project in question must be disclosed if provided by the trial sponsor or agents employed by the sponsor.

#### **F. Expert Testimony**

Provision of expert testimony must be disclosed when the testimony relates to the subject matter under consideration.

#### **G. Other Remuneration**

The value of trips, travel, gifts, or other in-kind payments not directly related to research activities must be disclosed if received from an entity having an investment, licensing, or other commercial interest in the subject matter under consideration and when received within 2 years of the activity or subject matter in question. De minimis payments totaling less than \$100 are excluded from disclosure requirements. These payments exclude research-related costs and travel.

## 2010 Faculty/Program and Steering/News Planning Committee Disclosure Index

The 2010 Gastrointestinal Cancers Symposium Program Committee has reviewed all presented disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict where they exist. Financial relationships reported by members of the 2010 Gastrointestinal Cancers Symposium Program and Steering Committees are also provided below. During all phases of planning for the Symposium, areas of conflict were managed through a peer-review process and/or through individual recusal when appropriate. Program and Steering Committee members are indicated with a dagger (†); News Planning Committee members are indicated with a double dagger (‡). Relationships are considered self-held and compensated unless otherwise noted. Relationships in the first column are considered employment relationships unless designated as a leadership position. I – Immediate Family Member; B – Myself and Immediate Family Member; U – Uncompensated; L – Leadership Position. Faculty who had not provided disclosure information by December 14 are indicated with an asterisk (\*).

Name	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Ahlquist, David A.		Exact Sciences	Exact Sciences		Exact Sciences		
Ajani, Jaffer A.		sanofi-aventis			sanofi-aventis; Taiho; NS Pharma; Adherex		
Arber, Nadir†	BioView (L); Micromedic (L)	GI View; Micromedic	Micromedic	Pfizer	Micromedic; Pfizer		
Blanke, Charles		ImClone Systems; Novartis; Pfizer; Raven Biotech; Roche; sanofi-aventis			Novartis		
Bresalier, Robert†		Avantis Medical (U); Novartis					
Brown, Gina							
Brugge, William R.		Boston Scientific			Biocompatibles		
Canto, Marcia							
Cervantes-Ruiperez, Andres				Merck Serono; Amgen; sanofi-aventis; Roche			
Chung, Daniel†‡		Myriad Labs		Ipsen			
Conlon, Kevin C.†					Nycomed		Amgen; AstraZeneca
Cunningham, David†		Amgen (U); AstraZeneca (U); Roche (U); sanofi-aventis (U)			Roche; Amgen; Merck Serono; sanofi-aventis		
Curley, Steven A.†							
Czito, Brian G.					Amgen; Genentech		
Dang, Chi V.		Agios Pharmaceuticals, Inc.					
de Gramont, Aimery H.*							
Der, Channing J.				GlaxoSmithKline	GlaxoSmithKline		Gloucester Pharmaceuticals; Thallion Pharmaceuticals
El-Khoueiry, Anthony B.*							

Name	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Ellis, Lee M.		Schering-Plough		Amgen; AstraZeneca; Bayer; Genentech; Genomic Health; Pfizer; Regeneron; Roche	ImClone Systems; sanofi-aventis		
Eng, Cathy†				Roche	Amgen; Bristol-Myers Squibb; sanofi-aventis		
Frilling, Andrea							
Geschwind, Jeff H.		Bayer; Biocompatibles; Biosphere Medical; Guerbet			Bayer; Biocompatibles; Biosphere Medical; Genentech; MDS Nordion		
Goldberg, Richard M.†		Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech; Genomic Health; ImClone Systems; Myriad; Oncothyreon; Pfizer; Poniard; sanofi-aventis		Genentech; Pfizer; sanofi-aventis	Abbott; Amgen; Enzon; Pfizer; sanofi-aventis		
Gores, Gregory J.				Bayer; Chugai; Conatus; Schering-Plough			
Grady, William M.†		Myriad Genetics					
Gunderson, Leonard L.†		OSI Pharmaceuticals					
Haddock, Michael G.†							
Hanash, Samir							
Hecht, J. R.					Amgen		
Herman, Joseph M.							
Hochwald, Steven N.†				Pfizer			
Jain, Rakesh K.	SynDevRx (L,U)	AstraZeneca; Dyax; Enlight Biosciences; Millennium	SynDevRx	Alnylam Pharmaceuticals; Pfizer	AstraZeneca; Dyax		
Jankowski, Janusz		AstraZeneca		AstraZeneca	AstraZeneca		
Kachnic, Lisa A.†		DOR BioPharma, Inc. (U)			sanofi-aventis		

## 2010 FACULTY DISCLOSURE INDEX

Name	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Laheru, Dan†		Concordia; Genentech; Bristol-Myers Squibb; GenVec (U)		Bristol-Myers Squibb; Genentech; sanofi-aventis	Bristol-Myers Squibb; Concordia; Genentech; GenVec		
Lenz, Heinz-Josef		Response Genetics; Genentech; Amgen; Merck; Novartis; sanofi-aventis; Pfizer; Bristol-Myers Squibb; ImClone Systems		Roche; Bristol-Myers Squibb; Lilly; sanofi-aventis; Novartis; Chiron; Genentech; Millennium; ImClone Systems; Pfizer; ICN; New Biotics; Bayer; AstraZeneca			
Lightdale, Charles J.							
Lowy, Andrew M.†							
Malfertheiner, Peter		Axcan		AstraZeneca; Abbott; Novartis; Nycomed			
Mamon, Harvey J.							
Marrero, Jorge A.†		Bayer			Bayer		
McLeod, Howard M.		Affymetrix; Medco Health Solutions; Myriad Genetics					
Merchant, Nipun B.							
Messersmith, Wells A.†		Celgene; EntreMed; Genentech; sanofi-aventis					
Minsky, Bruce D.		AstraZeneca; Bristol-Myers Squibb; Genentech; Merck & Co.; Roche; sanofi-aventis; Supratek		AstraZeneca; Bristol-Myers Squibb; Genentech; Roche; sanofi-aventis; Supratek			
Nelson, Heidi							
Philip, Philip A.		Bristol-Myers Squibb; ImClone; OSIP; sanofi-aventis			Genentech; Lilly; Pfizer; Roche		
Posner, Mitchell†*							
Punt, Cornelis J.		Roche; Merck Serono		Roche			
Regine, William†				Schering-Plough			

Name	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Rodriguez-Bigas, Miguel A.		Myriad Genetics					
Sahani, Dushyant V.				Bracco Diagnostics	GE Healthcare		
Schwarz, Roderich				sanofi-aventis			
Sharma, Prateek†				Olympus; Santarus; Takeda	BARRX Medical; Olympus; Takeda		
Sherman, Morris†		Bayer; Bristol-Myers Squibb		Bayer			
Shields, David J.							
Siu, Lillian L.		Amgen; Millennium			Abraxis; Bristol-Myers Squibb; Cyclacel; GlaxoSmithKline; Millennium; Novartis; Pfizer; Regeneron; Roche; Twinstrand Inc.		
Sonnenberg, Amnon							
Sticca, Robert P.‡							
Syngal, Sapna†				Myriad Genetics			
Talamonti, Mark S.‡							
Tuveson, David A.							
Uronis, Hope E.		Roche			Genentech; Roche; sanofi-aventis		
Valentini, Vincenzo†							
Valle, Juan W.							
Van Cutsem, Eric		Amgen; Merck; Novartis; Pfizer; Roche; sanofi-aventis			Merck Serono; Pfizer; Roche; sanofi-aventis		
van de Velde, Cornelis J.†					Pfizer		
Varadhachary, Gauri R.	Agennix (I)	Rexahn Pharmaceuticals	Agennix (I)		Rosetta Genomics		
Velculescu, Victor E.		Helicos Biosciences; Inostics (U)	Helicos Biosciences; Inostics				Beckman Coulter; Genomics; DxS Diagnostics; Genzyme
Wang, Thomas D.							
Wang, Timothy C.							
Waxman, Irving							
Weber, Sharon M.							
Willett, Christopher†							